A rational approach for selecting CD3-binding antibodies for T-cell engager development

post

Mai M, et al. Society for Immunotherapy of Cancer (SITC) Annual Meeting, November 2023

This poster describes a data-backed approach for the selection of CD3-binding antibodies for different tumor targets, highlighting that CD3 affinity alone is not sufficient to optimize T-cell engager (TCE) function. Here, we show how this platform was leveraged to generate TCEs for multiple targets, including prostate-specific membrane antigen (PSMA) and melanoma-associated antigen 4 (MAGE-A4).

DOI: 10.1136/jitc-2023-SITC2023.1367

AbCellera SITC 2023 Poster - T-cell Engager Platform
Download poster

Further reading:

  1. Bergqvist P, et al. J Immunother Cancer 2024;12(Suppl 2):A1–A1683. 
  2. Mai M, et al. Cancer Res (2024) 84 (6_Supplement): 1868. 
  3. Mai M, et al. Cancer Res (2023) 83 (7_Supplement): 1886. 
  4. DeVorkin L, et al. Cancer Res (2022) 82 (12_Supplement): 312. 
  5. DeVorkin L, et al. J Immunother Cancer (2022)10 (Suppl 2):A1–A1603.